|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current approaches to reduce or eliminate mitochondrial DNA mutations显示文摘Mitochondrial DNA(mt DNA)mutations have been implicated in a broad range of disorders which severely affect human health(Wallace,1999).Some drugs have been developed to slow down pathological changes of mitochondrial disorders.However,there is no effective treatment for patients with mt DNA mutations.mt DNA is less protected and has fewer repair mechanisms than nuclear DNA(n DNA).Such a reality results in a much higher | Liang Yang Tingfang Mei Xiaobing Lin Haite Tang Yi Wu Rui Wang Jinglei Liu Zahir Shah Xingguo Liu | 2016 | Science China(Life Sciences)2016，59，5： | 3 |
| 2 | Universal enzymatic numerical P systems with small number of enzymatic variables显示文摘Numerical P systems(for short, NP systems) are distributed and parallel computing models inspired from the structure of living cells and economics. Enzymatic numerical P systems(for short, ENP systems) are a variant of NP systems, which have been successfully applied in designing and implementing controllers for mobile robots. Since ENP systems were proved to be Turing universal, there has been much work to simplify the universal systems, where the complexity parameters considered are the number of membranes, the degrees of polynomial production functions or the number of variables used in the systems.Yet the number of enzymatic variables, which is essential for ENP systems to reach universality, has not been investigated. Here we consider the problem of searching for the smallest number of enzymatic variables needed for universal ENP systems. We prove that for ENP systems as number acceptors working in the all-parallel or one-parallel mode, one enzymatic variable is sufficient to reach universality; while for the one-parallel ENP systems as number generators, two enzymatic variables are sufficient to reach universality.These results improve the best known results that the numbers of enzymatic variables are 13 and 52 for the all-parallel and one-parallel systems, respectively. | Zhiqiang ZHANG Tingfang WU ANDrei PAUN Linqiang PAN | 2018 | Science China(Information Sciences)2018，61，9： | 2 |
| 3 | Magnesium-based materials in orthopaedics:material properties and animal models显示文摘As a new generation of medical metal materials,degradable magnesium-based materials have excellent mechanical properties and osteogenic promoting ability,making them promising materials for the treatment of refractory bone diseases.Animal models can be used to understand and evaluate the performance of materials in complex physiological environments,providing relevant data for preclinical evaluation of implants and laying the foundation for subsequent clinical studies.To date,many researchers have studied the biocompatibility,degradability and osteogenesis of magnesium-based materials,but there is a lack of review regarding the effects of magnesium-based materials in vivo.In view of the growing interest in these materials,this review briefly describes the properties of magnesium-based materials and focuses on the safety and efficacy of magnesium-based materials in vivo.Various animal models including rats,rabbits,dogs and pigs are covered to better understand and evaluate the progress and future of magnesium-based materials.This literature analysis reveals that the magnesium-based materials have good biocompatibility and osteogenic activity,thus causing no adverse reaction around the implants in vivo,and that they exhibit a beneficial effect in the process of bone repair.In addition,the degradation rate in vivo can also be improved by means of alloying and coating.These encouraging results show a promising future for the use of magnesium-based materials in musculoskeletal disorders. | Xirui Jing Qiuyue Ding Qinxue Wu Weijie Su Keda Yu Yanlin Su Bing Ye Qing Gao Tingfang Sun Xiaodong Guo | 2021 | Biomaterials Translational2021，2，3： | 1 |
| 4 | In situ bone regeneration with sequential delivery of aptamer and BMP2 from an ECM-based scaffold fabricated by cryogenic free-form extrusion显示文摘In situ tissue engineering is a powerful strategy for the treatment of bone defects.It could overcome the limitations of traditional bone tissue engineering,which typically involves extensive cell expansion steps,low cell survival rates upon transplantation,and a risk of immuno-rejection.Here,a porous scaffold polycaprolactone(PCL)/decellularized small intestine submucosa(SIS)was fabricated via cryogenic free-form extrusion,followed by surface modification with aptamer and PlGF-2_(123-144)*-fused BMP2(pBMP2).The two bioactive molecules were delivered sequentially.The aptamer Apt19s,which exhibited binding affinity to bone marrow-derived mesenchymal stem cells(BMSCs),was quickly released,facilitating the mobilization and recruitment of host BMSCs.BMP2 fused with a PlGF-2_(123-144)peptide,which showed“super-affinity”to the ECM matrix,was released in a slow and sustained manner,inducing BMSC osteogenic differentiation.In vitro results showed that the sequential release of PCL/SIS-pBMP2-Apt19s promoted cell migration,proliferation,alkaline phosphatase activity,and mRNA expression of osteogenesis-related genes.The in vivo results demonstrated that the sequential release system of PCL/SIS-pBMP2-Apt19s evidently increased bone formation in rat calvarial critical-sized defects compared to the sequential release system of PCL/SIS-BMP2-Apt19s.Thus,the novel delivery system shows potential as an ideal alternative for achieving cell-free scaffold-based bone regeneration in situ. | Tingfang Sun Chunqing Meng Qiuyue Ding Keda Yu Xianglin Zhang Wancheng Zhang Wenqing Tian Qi Zhang Xiaodong Guo Bin Wu Zekang Xiong | 2021 | Bioactive Materials2021，6，11： | 1 |
| 5 | PLSCR1 promotes apoptosis and clearance of retinal ganglion cells in glaucoma pathogenesis显示文摘Glaucoma is the leading cause of irreversible blindness worldwide.In the pathogen-esis of glaucoma,activated microglia can lead to retinal ganglion cells(RGCs)apoptosis and death,however,the molecular mechanisms remain largely unknown.We demonstrate that phospholipid scramblase 1(PLSCR1)is a key regulator promoting RGCs apoptosis and their clearance by microglia.As evidenced in retinal progenitor cells and RGCs of the acute ocular hypertension(AOH)mouse model,overexpressed PLSCR1 induced its translocation from the nucleus to the cytoplasm and cytomembrane,as well as elevated phosphatidylserine exposure and reactive oxygen species generation with subsequent RGCs apoptosis and death.These damages were effectively attenuated by PLSCR1 inhibition.In the AOH model,PLSCR1 led to an increase in M1 type microglia activation and retinal neuroinflammation.Upregulation of PLSCR1 resulted in strongly elevated phagocytosis of apoptotic RGCs by activated microglia.Taken together,our study provides important insights linking activated microglia to RGCs death in the glaucoma pathogenesis and other RGC-related neurodegenerative diseases. | Jingyi Luo Qing Lian Deliang Zhu Minglei Zhao Tingfang Mei Bizhi Shang Zeqiu Yang Chujun Liu Wenchang Xu Lan Zhou Keling Wu Xinqi Liu Yuhua Lai Fuxiang Mao Weihua Li Chengguo Zuo Kang Zhang Mingkai Lin Yehong Zhuo Yizhi Liu Lin Lu Ling Zhao | 2023 | Genes & Diseases2023，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员